1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,470 | 1,470 | 24.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | ABBISKO-B Subsidiary Presents 6 Preclinical and Translational Research Findings at AACR | 2 | AASTOCKS | ||
| Do | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS SHOWCASES SIX RESEARCH ADVANCES AT 2026 AACR, HIGHLIGHTING PAN-KRAS, 4TH GENERATION EGFR, ... | 1 | HKEx | ||
| Di | ABBISKO-B (02256): PLACING OF NEW SHARES UNDER THE GENERAL MANDATE | 2 | HKEx | ||
| 08.04. | ABBISKO-B (02256): GRANT OF OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME AND GRANT OF RSUS UNDER THE 2019 SHARE INCENTIVE PLAN | 1 | HKEx | ||
| 31.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED ORPHAN DRUG DESIGNATION BY EMA FOR HEPATOCELLULAR CARCINOMA | 2 | HKEx | ||
| 31.03. | Abbisko Therapeutics Co., Ltd.: Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children | 90 | PR Newswire | SHANGHAI, March 31, 2026 /PRNewswire/ -- On 30 March, 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that... ► Artikel lesen | |
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 30.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR2/3 INHIBITOR ABSK061 RECEIVES FDA IND CLEARANCE FOR ACHONDROPLASIA IN CHILDREN | 1 | HKEx | ||
| 19.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR2/3 INHIBITOR ABSK061 GRANTED ORPHAN DRUG DESIGNATION BY FDA FOR ACHONDROPLASIA | 6 | HKEx | ||
| 16.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' IRPAGRATINIB COMBINED WITH TARGETED-IMMUNOTHERAPY COMPLETES FIRST PATIENT DOSING IN ... | 1 | HKEx | ||
| 11.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FDA GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR FGFR2/3 INHIBITOR ABSK061 | 8 | HKEx | ||
| 09.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - THE LANCET PUBLISHES GLOBAL PHASE 3 MANEUVER STUDY RESULTS OF PIMICOTINIB | 1 | HKEx | ||
| 04.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' ORAL SMALL-MOLECULE KRAS G12D INHIBITOR ABSK141 COMPLETED FIRST PATIENT DOSING | 1 | HKEx | ||
| 03.03. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ... | - | HKEx | ||
| 02.03. | ABBISKO-B (02256): (1) ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025; AND (2) CHANGE OF THE JOINT COMPANY SECRETARIES, AUTHORISED REPRESENTATIVE ... | 1 | HKEx | ||
| 11.02. | ABBISKO-B (02256): DATE OF BOARD MEETING | 1 | HKEx | ||
| 11.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB COMPLETED FIRST U.S. PATIENT DOSING IN THE EXPANSION PART OF A GLOBAL PHASE I ... | 1 | HKEx | ||
| 10.02. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FGFR4 INHIBITOR IRPAGRATINIB GRANTED FDA FAST TRACK DESIGNATION FOR HCC PATIENTS | 3 | HKEx | ||
| 13.01. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - FDA ACCEPTANCE OF THE NDA FOR PIMICOTINIB FOR THE TREATMENT OF TGCT | 1 | HKEx | ||
| 13.01. | Abbisko Therapeutics Announces FDA Acceptance Of Pimicotinib NDA For Tenosynovial Giant Cell Tumor | 583 | AFX News | HONG KONG (dpa-AFX) - Abbisko Therapeutics Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has formally accepted the New Drug Application (NDA) for pimicotinib (ABSK021).... ► Artikel lesen | |
| 13.01. | Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor | 342 | PR Newswire | SHANGHAI, Jan. 12, 2026 /PRNewswire/ -- 13 January 2026 (Beijing Time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| EVOTEC | 5,350 | -0,93 % | Evotec hebt ab: Kursziel übertroffen, Experten uneinig - Wie geht es jetzt weiter? | ||
| VERA THERAPEUTICS | 37,700 | -1,80 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 5,020 | +24,57 % | What's Going On With Enveric Biosciences Stock On Friday? | ||
| NUVALENT | 104,53 | -3,28 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| BIONTECH | 90,15 | +0,22 % | BioNTech Aktie: Kurs dreht auf! Zulassungsantrag, Pipeline-Power und ein Einstiegssignal! | © Foto: Pexels (Symbolbild)Lange war BioNTech für viele Anleger ein Sorgenkind. Der Rückgang des Corona-Geschäfts drückte auf den Kurs, der Abgang der Gründer sorgte für Unsicherheit. Dann kam der Absturz... ► Artikel lesen | |
| FIRST TRACKS BIOTHERAPEUTICS | 18,160 | -4,47 % | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 29,760 | +2,62 % | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,68 %) liegt der Kurs bei 1,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.